DA Davidson cuts BellRing Brands stock price target on competition By Investing.com

BellRing Brands posted a Q2 fiscal 2026 EPS miss of 56.25% at $0.14 versus $0.32 expected, while revenue came in at $598.7 million versus $608.82 million consensus. DA Davidson slashed its price target to $13 from $34, citing competitive pressure and another disappointing quarter; S&P also downgraded the credit rating to 'B+' from 'BB-' and expects adjusted EBITDA to fall more than 30% by fiscal 2026. The stock trades near $9.15, close to its 52-week low, after an 86% decline over the past year.

Analysis

BRBR is transitioning from a “growth at any price” name into a balance-sheet-and-multiple compression story: once the market loses confidence in category leadership, the equity no longer trades on long-duration brand optionality but on near-term EBITDA durability. That matters because the market is likely still pricing in a stabilization scenario, while the repeated estimate cuts imply the next leg is about earnings resets, not just slower growth. In consumer staples, that usually creates a one-way flow regime: systematic de-rating, lower index ownership, and less support from discretionary growth funds.

The second-order winner is not necessarily a single named competitor, but the broader private-label and value-protein set: if household penetration is still expanding, consumers are not abandoning the category, they are reallocating within it. That means promo intensity can remain elevated longer than management teams expect, compressing margins across adjacent better-for-you snacks and ready-to-drink protein shelves. Suppliers with meaningful exposure to sweeteners, dairy inputs, and co-manufacturing capacity could also see mix pressure if the branded leader cuts production plans or shifts to more promotional pack architecture.

The key catalyst window is the next 1-2 quarters, when guidance revisions and sell-side model cuts can force valuation to converge toward a mid-single-digit EBITDA multiple rather than the current “cheap P/E” narrative. A near-term squeeze higher is possible if weekly scanner data shows sequential share stabilization, but the burden of proof is high: one clean quarter is less important than evidence that promo elasticity has normalized. The contrarian view is that the move may be partially overdone only if household penetration keeps rising and the brand can defend volume with modest margin sacrifice; otherwise, the market is likely still underestimating how long it takes for a damaged power brand to regain shelf credibility.

Key Decisions for Investors

• Short BRBR on any relief rally back toward the low-teens; target a 3-6 month move to single-digit or low-teens equity value if EBITDA continues to reset. Risk/reward improves on failed bounce after earnings or channel checks.
• For event-driven expression, buy BRBR downside via 3-6 month put spreads rather than outright shorting stock; this limits borrow/short squeeze risk while capturing another guidance cut scenario.
• Pair trade: long a broad consumer staple basket or a stronger protein-adjacent name with cleaner execution, short BRBR. The relative trade benefits if category growth persists but share losses continue to punish the weakest branded operator.
• Use scanner data as the trigger, not headlines: if share trends do not stabilize over the next 4-8 weeks, add to the short; if weekly velocity inflects, cover quickly because the stock’s low base can produce violent bear-market rallies.
• Monitor the high-yield/levered credit read-through: if agency or bond spreads widen further, equity downside likely accelerates over the next 1-2 quarters as refinancing and capex flexibility become part of the equity story.